Report: FICO develops Medication Adherence Score
NEW YORK — A company best known for keeping credit scores on consumers is planning to rate their medication adherence as well, according to published reports.
The New York Times reported that FICO developed the FICO Medication Adherence Score, designed to predict when patients might not use their medications properly or take their doses. Payers will use the scores, based on such data as homeownership and employment, to determine which patients should receive various reminders to take their drugs.
Medication nonadherence is considered a nationwide health crisis, costing the U.S. healthcare system an estimated $290 billion per year. According to the National Consumers League, three-fourths of Americans taking prescription drugs are not adherent to their medication regimens.
NDEP updates website with new videos
WASHINGTON — The Department of Health and Human Services’ National Diabetes Education Program has unveiled a series of videos designed to help people make lifestyle changes and cope with the demands of diabetes.
The NDEP said the three- to five-minute videos, which can be accessed at YourDiabetesInfo.org/HealthSense, address such topics as setting goals to improve health, living with diabetes and finding the support you need, as well as segments on diabetes prevention and physical activity. The launch of the videos coincides with the redesign of the NDEP’s online library of behavior change resources.
“For more than 14 years, the NDEP has been [at] the forefront of raising awareness about diabetes, but more needs to be done to provide resources and tools to support healthcare providers and their patients when it comes to achieving and sustaining health goals,” said Griffin Rodgers, director of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, one of the sponsors of NDEP.
The NDEP is jointly sponsored by the National Institutes of Health and the Centers for Disease Control and Prevention.
Pfizer, Acura get FDA OK for Oxecta
NEW YORK — The Food and Drug Administration has approved a medication designed to treat acute and chronic moderate to severe pain, where the use of an opioid analgesic is suitable.
Pfizer and Acura Pharmaceuticals said that their drug Oxecta (oxycodone HCl, USP tablets) is the first tamper-resistant medication designed to deter abuse and misuse with Aversion technology, which is being licensed by Pfizer from Acura.
Opioid medications are an important treatment option for patients with moderate to severe pain who are not adequately managed by other pain treatments, Pfizer and Acura said, noting that abuse and misuse of opioids is a serious public health issue.
"We are excited to be partnered with Pfizer to bring Oxecta to patients who need opioids to manage their pain," Acura’s interim president and CEO Robert Jones said. "Acura is focused on developing technologies that are intended to potentially deter abuse and misuse."